Ferring Pharma has said that it will establish another formulation unit in Hyderabad for manufacturing its product PENTASA (Mesalazine). It will invest about €60 million over the next 2-3 years in this manufacturing facility.

It said PENTASA used for the treatment and long-term management of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. It is prescribed to treat the mild to moderate symptoms of active IBD, as well as used widely as maintenance therapy to reduce the risk of recurrent attacks. PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, with the exception of the US. In the US, Shire US, sells PENTASA under a trademark license from Ferring.

Ferring produces the active pharmaceutical ingredient (API) Mesalazine at two of its manufacturing facilities in Denmark and in India (near Mumbai).

here is company details.

 

NOTE :You need to login first to access this feature.